Yongqian Shu

Sun Yat-sen University — China

Biochemistry, Genetics and Molecular Biology · Life Sciences

38h-index5.6kcitations108works3.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related molecular mechanisms research(36), RNA modifications and cancer(24), Circular RNAs in diseases(18), MicroRNA in disease regulation(17), Lung Cancer Treatments and Mutations(10)

Publications108 total

FSTL1 is a prognostic marker and promotes invasion and metastasis of colon cancer
Discover Oncology·2025Open Access
Effects of Tanshinone IIA on Calcium Overload and Pyroptosis in Radiation-induced Heart Disease Evaluated in Vivo and in Vitro
Radiation Research·2025
Machine Learning-Based Prognostic Model for Gastric Cancer Using Integrated Multi-Omics Data
Cancer Investigation·2025
SENP1 drives glycolysis and cisplatin resistance in gastric cancer via desumoylating ENO1
Journal of Experimental & Clinical Cancer Research·2025Open Access
P3.12.07 Rezivertinib in EGFR-Mutated NSCLC Patients With Cns Metastases: Cns Efficacy From Phase 3 RAZOR Study
Journal of Thoracic Oncology·2025· 1 cited
Exploration of the association between <i>SF3B4</i> and <i>HMGB1</i> expression and the clinicopathological features and prognosis of gastric cancer
World Journal of Gastrointestinal Oncology·2025Open Access
Illustrating potential actionable drug targets of head and neck tumors based on comprehensive genomic landscape of 386 samples
Oral Oncology·2025
Safety of fruquintinib in young and late-elderly Chinese patients with colorectal cancer in real-world clinical practice: Age subgroup analysis of a fruquintinib phase IV study.
Journal of Clinical Oncology·2025
Safety of fruquintinib monotherapy and combination therapy in Chinese patients with colorectal cancer in real-world clinical practice: A subgroup analysis from phase IV study.
Journal of Clinical Oncology·2025
Pucotenlimab in high microsatellite instability/mismatch repair–defificient (MSI-H/ dMMR) solid tumors: Results update from a multicenter, phase II, open-label study.
Journal of Clinical Oncology·2025
Investigation of the DNA Methylation-Modified 8–17 DNAzyme Functions via Sensitive Catalytic Hairpin Self-Assembly Reaction
ACS Sensors·2025· 1 cited
DialogueReason: Rule-Based RL Sparks Dialogue Reasoning in LLMs
arXiv (Cornell University)·2025Open Access
Integrating single-cell RNA-Seq and bulk RNA-Seq data to explore the key role of fatty acid metabolism in hepatocellular carcinoma
Scientific Reports·2025· 4 citedOpen Access
IL-17 triggers PD-L1 gene transcription in NSCLC cells via TRIM31-dependent MEF2C K63-linked polyubiquitination
BMC Cancer·2025· 2 citedOpen Access
Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial
Signal Transduction and Targeted Therapy·2024· 10 citedOpen Access
[DFNB9 gene therapy: from bench to bedside].
PubMed·2024
A Novel Delivery Approach of Clinical Inner Ear Gene Therapy
Otology & Neurotology·2024· 5 cited
Crispr-mediated genome editing reveals a preponderance of non-oncogene addictions as targetable vulnerabilities in pleural mesothelioma
Lung Cancer·2024· 3 cited
METTL14 regulates CD8+T-cell activation and immune responses to anti‐PD‐1 therapy in lung cancer
World Journal of Surgical Oncology·2024· 9 citedOpen Access
First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study
Signal Transduction and Targeted Therapy·2024· 39 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Tongpeng Xu(14), Pei Ma(12), Rui Xia(8), Erbao Zhang(8), Wenming Chen(7), Tao Yu(6), Tongshan Wang(6), Ming Sun(6), Mingde Huang(6), Wei De(6), Wei Zhu(5), Ling Ma(5), Liang Han(3), Rong Kong(3), Fuzhen Qi(3), Xin Zhou(3), Jing Xu(3), Zebo Huang(3), You Shuai(3), Wenyu Wang(3)